About Us
Science
Pipeline
- HMBD-001
- HMBD-501
News
Partnering
Patients
Contact
Join Us

AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

by communications@hummingbirdbio.com on 25 April, 2024 in HMBD-001, Posters, Posters - 2024, Publications & Posters

<< Back to Publications

AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization
interface effectively inhibits tumor growth in pre-clinical
models with potentially oncogenic HER3 mutations

25 April, 2024

VIEW POSTER

<< Back to News

PubPosts-HMBD-001 RelatedNews-HMBD-001

Previous Reading

Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

Next Reading

AACR 2024: The VISTA blocking antibody HMBD-002 promotes type-I interferon signaling and drives anti-tumor responses through macrophage reprograming and cytotoxic CD8+ T cell activation

Subscribe to our updates

*indicates required

*Email Address

*First Name

*Last Name

*Company

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

Leave a Reply Cancel reply

AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization
interface effectively inhibits tumor growth in pre-clinical
models with potentially oncogenic HER3 mutations